Occurrence of de novo ABL kinase domain mutations in primary bone marrow cells after BCR-ABL gene transfer and Imatinib mesylate selection

被引：0
|
作者：
S Flamant
A G Turhan
机构：
[1] INSERM U362,
[2] Unite de thérapie cellulaire,undefined
[3] Institut Gustave Roussy,undefined
来源：
Leukemia | 2005年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1265 / 1267
页数：2
相关论文
共 50 条
  • [11] An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate
    T Leguay
    V Desplat
    V Lagarde
    G Marit
    J Reiffers
    F-X Mahon
    Leukemia, 2005, 19 : 1671 - 1673
  • [12] Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib
    Chahardouli, Bahram
    Zaker, Farhad
    Mousavi, Seied Asadollah
    Saffari, Zeinab
    Nadali, Fatemeh
    Ostadali, Mohammadreza
    Ghadimi, Habibeh
    Alimoghaddam, Kamran
    Ghavamzade, Ardeshir
    Rostami, Shahrbano
    HEMATOLOGY, 2013, 18 (06) : 327 - 332
  • [13] ABSENCE OF BCR-ABL KINASE DOMAIN MUTATIONS IN CHRONIC MYELOCYTIC LEUKEMIA (CML) QATARI PATIENTS ON IMATINIB MESYLATE (IM) TREATMENT
    Al-Dewik, I.
    Jewell, P.
    Elayoubi, R.
    Morsi, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 532 - 532
  • [14] Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients
    Chandrasekhar, Chodimella
    Kumar, Pasupuleti Santhosh
    Sarma, Potukuchi Venkata Gurunadha Krishna
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [15] Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients
    Chodimella Chandrasekhar
    Pasupuleti Santhosh Kumar
    Potukuchi Venkata Gurunadha Krishna Sarma
    Scientific Reports, 9
  • [16] Spectrum of BCR-ABL Kinase Domain Mutations in North Macedonia in Patients With CML Resistant to Imatinib
    Stojanovska-Jakimovska, Simona
    Cvetanoski, Milche
    Ridova, Nevenka
    Trajkova, Sanja
    Popova-Labachevska, Marija
    Mojsovska, Tara
    Dukovski, Dushko
    Pivkova-Veljanovska, Aleksandra
    Stojanovski, Zlate
    Krstevska-Balkanov, Svetlana
    Pavkovic, Marica
    Chadievski, Lazar
    Panovska-Stavridis, Irina
    Ivanovski, Martin
    Gjorgievska, Emilija
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S375 - S375
  • [17] Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib
    Irving, JAE
    O'Brien, S
    Lennard, AL
    Minto, L
    Lin, F
    Hall, AG
    CLINICAL CHEMISTRY, 2004, 50 (07) : 1233 - 1237
  • [18] Imatinib mesylate does not inhibit BCR-ABL kinase activity in CML stem cells in vitro.
    Elrick, LJ
    Hamilton, A
    Deininger, MW
    Holyoake, TL
    BLOOD, 2004, 104 (11) : 546A - 546A
  • [19] Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
    Elias, Marjanu Hikmah
    Baba, Abdul Aziz
    Husin, Azlan
    Abdullah, Abu Dzarr
    Hassan, Rosline
    Sim, Goh Ai
    Wahid, S. Fadilah Abdul
    Ankathil, Ravindran
    HEMATOLOGY REPORTS, 2012, 4 (04) : 86 - 90
  • [20] BCR-ABL kinase domain mutations & SNPs in imatinib resistant or intolerant chronic myeloid leukaemia patients
    O'Connor, Lisa M.
    Langabeer, Stephen
    McCann, Shaun R.
    Conneally, Eibhlin
    BLOOD, 2007, 110 (11) : 699A - 700A
12345